Haemonetics Co. (NYSE:HAE) Shares Sold by California Public Employees Retirement System

California Public Employees Retirement System reduced its stake in Haemonetics Co. (NYSE:HAE) by 3.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 218,361 shares of the medical instruments supplier’s stock after selling 7,015 shares during the period. California Public Employees Retirement System’s holdings in Haemonetics were worth $17,050,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the stock. Pictet Asset Management Holding SA grew its stake in shares of Haemonetics by 16.4% in the fourth quarter. Pictet Asset Management Holding SA now owns 6,963 shares of the medical instruments supplier’s stock valued at $544,000 after buying an additional 979 shares in the last quarter. Norges Bank acquired a new stake in Haemonetics in the fourth quarter valued at approximately $32,803,000. Zions Bancorporation N.A. raised its stake in shares of Haemonetics by 56.3% during the fourth quarter. Zions Bancorporation N.A. now owns 40,996 shares of the medical instruments supplier’s stock valued at $3,201,000 after purchasing an additional 14,762 shares during the period. KLP Kapitalforvaltning AS acquired a new position in shares of Haemonetics during the fourth quarter worth $789,000. Finally, Quantbot Technologies LP purchased a new position in shares of Haemonetics in the fourth quarter valued at $345,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. JMP Securities dropped their price target on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a research note on Friday, February 7th. Barrington Research dropped their target price on Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a research note on Saturday, February 15th. Raymond James restated a “strong-buy” rating and set a $115.00 price objective (down previously from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. Finally, Needham & Company LLC cut their target price on Haemonetics from $108.00 to $104.00 and set a “buy” rating on the stock in a research report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $101.22.

Haemonetics Stock Performance

HAE stock opened at $60.80 on Friday. The firm has a market cap of $3.05 billion, a P/E ratio of 23.94, a P/E/G ratio of 1.11 and a beta of 0.43. The stock’s 50 day simple moving average is $65.01 and its 200 day simple moving average is $74.27. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a 12-month low of $58.80 and a 12-month high of $97.97.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. As a group, equities research analysts predict that Haemonetics Co. will post 4.55 EPS for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.